Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma
Antineoplastic Combined Chemotherapy Protocols
Most patients with progressive disease after treatment with iodine I-131 tositumomab were able to receive subsequent therapy, including cytotoxic chemotherapy and stem cell transplantation.
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency